AGI Trial Site Registry

AGI-TSR is an online database of specialized sites that see patients with ataxias. It holds site-level information relevant to clinical studies, including trial experience, information on personnel, facilities, and ataxia patient populations at the participating sites around the globe in a readily available, standardized fashion. It does not contain identifiable patient data.

This information can help identify sites meeting specific criteria for a range of purposes:

  • enabling the pharmaceutical industry and clinical investigators select prospective sites for multi-centre clinical trials,
  • permitting the identification of potential partners in research collaborations,
  • and supporting the collection and analysis of site-specific data for coordination and analysis in research networks.

AGI-TSR is using the technical platform of the Care and Trial Site Registry (CTSR).  This includes the development of a FAIR data endpoint, enabling interoperability with other rare disease infrastructures such as the Virtual Platform of the European Joint Programme on Rare Diseases.

Register your Site at the AGI-TSR!

Benefits for registered sites include:

  • Increasing visibility of your site among patients, researchers, clinicians, and industry
  • Potential participation in clinical trials and research projects
  • Participation in an international network of centers

To register your site, please follow this link:

Do you need information on Ataxia sites for your research?

Benefits for industry and researchers:

  • A single point of access for clinical trial or research project feasibility information
  • Draw on an existing network of specialized ataxia sites for your research project
  • Improve recruitment by combining site-level data with information from patient registries, in a joint enquiry with registries hold by AGI partners

 

AGI-TSR Dataset Details

  1. Genetic ataxia subtypes (total number, <18, >=18 (legally motivated, consent), ambulatory/non-ambulatory (estimate)). Selection criterion: most likely to be treatment-trial relevant within the next 5 years.
  2. Clinical Trials Experience
  3. Availability of the facilities

Please find the full dataset here.